logo

Audentes Therapeutics, Inc. (BOLD)



Trade BOLD now with
  Date
  Headline
3/9/2018 8:11:06 AM Wedbush Is Raising Audentes Therapeutics, Inc. (BOLD) Q1 18 Estimate To -0.75 From -0.81
3/9/2018 8:10:44 AM Wedbush Reiterates Audentes Therapeutics, Inc. (BOLD) At Outperform With $56 Price Target
2/12/2018 8:15:46 AM Audentes Announces Dosing Of First Patient In VALENS, Phase 1/2 Trial Of AT342 For Treatment Of Crigler-Najjar Syndrome
2/6/2018 7:41:40 PM Audentes Therapeutics Announces Selection Of Optimized Clinical Development Candidate For Pompe Disease Program
1/24/2018 7:54:15 PM Audentes Therapeutics Announces Pricing Of Underwritten Public Offering Of 5.75 Mln Shares At $35.00/shr
1/23/2018 4:07:47 PM Audentes Therapeutics Announces Proposed Public Offering Of Common Stock
1/4/2018 7:04:26 AM Audentes Announces Positive Interim Data From First Dose Cohort Of ASPIRO
11/15/2017 11:34:04 AM Wedbush Is Cutting Audentes Therapeutics, Inc. (BOLD) FY17 Estimate To -3.44 From -3.38
11/15/2017 11:33:35 AM Wedbush Is Lowering Audentes Therapeutics, Inc. (BOLD) Q4 17 Estimate To -0.86 From -0.85
5/15/2017 6:59:45 PM Wedbush Is Lowering Audentes Therapeutics, Inc. (BOLD) 2018 Estimate To -3.21 From -3.19
5/15/2017 6:59:22 PM Wedbush Is Lowering Audentes Therapeutics, Inc. (BOLD) Q4 18 Estimate To -0.83 From -0.82
5/15/2017 6:58:52 PM Wedbush Is Lowering Audentes Therapeutics, Inc. (BOLD) Q3 18 Estimate To -0.81 From -0.80
5/15/2017 6:58:32 PM Wedbush Is Cutting Audentes Therapeutics, Inc. (BOLD) Q2 18 Estimate To -0.80 From -0.79
5/15/2017 6:57:22 PM Wedbush Is Lowering Audentes Therapeutics, Inc. (BOLD) Q1 18 Estimate To -0.78 From -0.77
5/15/2017 6:56:57 PM Wedbush Is Increasing Audentes Therapeutics, Inc. (BOLD) 2017 Estimate To -3.41 From -3.48